James P. Wilmot Cancer Center - Developmental Therapeutics Review - Q1 2011

Global Markets Direct, March 2011, Pages: 49

James P. Wilmot Cancer Center – Developmental Therapeutics Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “James P. Wilmot Cancer Center – Developmental Therapeutics Review – Q1 2011” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by James P. Wilmot Cancer Center.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of James P. Wilmot Cancer Center with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of James P. Wilmot Cancer Center’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.

Reasons to buy

- Identify new drug targets and therapeutic classes in James P. Wilmot Cancer Center’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate James P. Wilmot Cancer Center’s position with total access to a detailed information on its therapeutic products development.
- Assess the growth potential of James P. Wilmot Cancer Center in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with James P. Wilmot Cancer Center.
- Avoid Intellectual Property Rights related issues.

List of Tables
List of Figures
James P. Wilmot Cancer Center Snapshot
James P. Wilmot Cancer Center Overview
Key Information
Key Facts
James P. Wilmot Cancer Center – Research and Development Overview
Key Therapeutic Areas
James P. Wilmot Cancer Center – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
James P. Wilmot Cancer Center – Pipeline Products Glance
James P. Wilmot Cancer Center Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
James P. Wilmot Cancer Center – Drug Profiles
aldesleukin + rituximab
Product Description
Mechanism of Action
R&D Progress
Amifostine + Paclitaxel
Product Description
Mechanism of Action
R&D Progress
Anti-thymocyte Globulin + Therapeutic Allogeneic Lymphocytes + Cyclophosphamide + Fludarabine + Mycophenolate Mofetil + Tacrolimus
Product Description
Mechanism of Action
R&D Progress
Fluorouracil + Leucovorin calcium + Oxaliplatin + GM-CSF
Product Description
Mechanism of Action
R&D Progress
Iressa
Product Description
Mechanism of Action
R&D Progress
Luorouracil + Leucovorin + Oxaliplatin + GM-CSF
Product Description
Mechanism of Action
R&D Progress
Rituxan + Aldesleukin
Product Description
Mechanism of Action
R&D Progress
Rituxan + IL-2
Product Description
Mechanism of Action
R&D Progress
Velcade
Product Description
Mechanism of Action
R&D Progress
vinorelbine + bevacizumab
Product Description
Mechanism of Action
R&D Progress
Anti-Thymocyte Globulin + Rapamycin
Product Description
Mechanism of Action
R&D Progress
anti-thymocyte globulin + sirolimus
Product Description
Mechanism of Action
R&D Progress
CLAG Regimen + Gleevec + Filgrastim
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Cladribine + Cytarabine + Imatinib mesylate
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Cladribine + Cytarabine + Imatinib mesylate
Product Description
Mechanism of Action
R&D Progress
imatinib mesylate + cladribine + cytarabine
Product Description
Mechanism of Action
R&D Progress
Recombinant Interferon Gamma
Product Description
Mechanism of Action
R&D Progress
Thymoglobulin + Sirolimus
Product Description
Mechanism of Action
R&D Progress
James P. Wilmot Cancer Center – Pipeline Analysis
James P. Wilmot Cancer Center – Pipeline Products by Therapeutic Class
James P. Wilmot Cancer Center - Pipeline Products By Target
James P. Wilmot Cancer Center – Pipeline Products by Route of Administration
James P. Wilmot Cancer Center – Pipeline Products by Molecule Type
James P. Wilmot Cancer Center - Dormant Projects
James P. Wilmot Cancer Center – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake
• Brain Tumor – Pipeline Review, H1 2013
• Oncology Intelligence: A Comprehensive Report for Decision Making
• Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013